EDITORIAL PROTOCOL / VERSION 01
One Desk, Two Ledgers
Clinical evidence and material quality are tracked separately so that neither can borrow certainty from the other.
What this site is
Clean Peptide Labs is an independent editorial digest covering four peptide files under one question: what does “clean” actually mean when contamination, adulteration, and degradation can change a research sample? It is not a laboratory, clinic, pharmacy, manufacturer, or vendor. It does not sell products, evaluate individual certificates, or provide medical guidance.
The name is a standard of inquiry, not a commercial claim. Every page separates two ledgers. The evidence ledger records model, study design, population, comparator, duration, effect size, and uncertainty. The material ledger records what would be needed to support identity, content, impurity profile, microbiological quality, and stability. A positive entry in one ledger does not fill a blank in the other.
That framework is especially useful across this roster because the evidence is intentionally uneven. BPC-157 is mainly preclinical. Retatrutide has randomized Phase 2 data but is investigational. GHK-Cu has limited topical human evidence and a formulation problem. Tirzepatide has large randomized trials and an approved-product baseline.
How to read the files
Each technical page begins with a plain-language summary, then moves through molecular identity, mechanism, published findings, reported experiences, cautions, and the compound’s role in the quality framework. Quantitative statements carry numbered citations linked to the shared reference register. Study amounts are reported only when they are part of a cited protocol; they are not recommendations.
Evidence terms are used deliberately. In vitro means outside a living organism, such as a cell assay. Preclinical generally means animal or laboratory work conducted before robust human testing. A randomized controlled trial compares assigned groups to reduce bias. A meta-analysis pools multiple studies, which can improve precision but still inherits limitations in the underlying trials. An anecdote is a self-report without those controls. Where community experience appears, it is labeled anecdotal, not clinical evidence.
The pages also distinguish purity from quality. Purity is one analytical dimension. It does not independently prove identity, concentration, sterility, endotoxin control, or stability. Reports are most useful when they identify the sample and lot, name the method, state units and acceptance limits, and make uncertainty visible.
Editorial stance
The governing rule is to report no stronger conclusion than the study design permits. Cell mechanisms are not translated into human outcomes without data. Animal findings remain animal findings. Small pilots are not described as definitive. Active-comparator and placebo-controlled trials are identified, and effect sizes retain their time points and populations. Regulatory status is treated as a factual boundary rather than a proxy for whether a molecule is scientifically interesting.
The same restraint applies to testing. A certificate is not accepted as self-interpreting. The relevant questions are which sample was tested, by whom, using what method, against which acceptance rule, and how the result maps to the claim. No single method can rule out every contamination, adulteration, or degradation pathway.
Corrections and source questions can be directed through the editorial contact page. The goal is a compact, auditable reading environment in which the numbers do the persuasive work and uncertainty remains part of the result.